A Phase 2, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received At Least One Prior Chemotherapy Regimen

Trial Profile

A Phase 2, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received At Least One Prior Chemotherapy Regimen

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (data cut off date Oct 26, 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 12 Apr 2017 Planned End Date changed from 1 Jun 2017 to 30 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top